Last updated: July 28, 2026
Pregnyl is a branded formulation of urinary human chorionic gonadotropin (hCG). It is used in infertility and hypogonadism indications, including assisted reproduction support and (in some geographies) hypogonadotropic hypogonadism in men. A comprehensive, date-stamped clinical-trials update and a reliable market projection require current public datasets for (1) “Pregnyl” brand-specific studies, (2) label-specific indications by country, (3) Orange Book and payer-market data by geography, and (4) current patent and exclusivity status. No such dataset is provided in the request, and an accurate “as of” update cannot be produced without it.
Clinical trials update for Pregnyl: What studies are currently recruiting or completed?
H1-subsection: Featured “Pregnyl” brand trial search status
- Public trial databases must be queried by brand name “Pregnyl” and by active ingredient “chorionic gonadotropin” with a filter for manufacturing sponsor(s).
- A clinical-trials update should report, per study:
- NCT number
- phase (I/II/III/IV)
- indication (e.g., ovulation induction, ART trigger support, male hypogonadotropic hypogonadism)
- route and dose form (commonly vials for IM/SC use depending on region)
- trial start and primary completion dates
- endpoints and results status
Market reality check: why a Pregnyl-specific trials update must be tied to brand or sponsor
- The hCG market includes multiple commercial products and biosimilars/alternatives depending on region and sourcing.
- Many studies are filed under the active ingredient or sponsor rather than the brand name, so a “Pregnyl” brand update must be sourced from brand-tagged records.
Given the absence of any trial registry snapshot or sponsor/indication list in the input, a complete and accurate trials update cannot be generated.
Market analysis for Pregnyl: How big is the hCG infertility and hypogonadism market where Pregnyl competes?
H2-subsection: How to structure market analysis
A market analysis for Pregnyl must segment by:
- Geography (US/EU/UK/LatAm/ME/Asia-Pacific)
- Indication
- assisted reproduction support (ovulation triggering and luteal support roles vary by protocol)
- ovulation induction
- male hypogonadotropic hypogonadism
- Competitor set
- urinary hCG brands
- recombinant hCG where marketed
- gonadotropin analogs used as substitutes in specific protocols
Commercial drivers that typically govern hCG product performance
- IVF and ART cycle volumes and protocol mix
- Availability and pricing of urinary hCG vs recombinant alternatives
- Guideline and clinician preference in ovulation induction and hypogonadism
- Supply reliability and manufacturing capacity for urinary-derived gonadotropins
Without (a) a specified geography, (b) a defined competitor set, and (c) a current unit and price dataset, any market-size estimate would be speculative.
When does Pregnyl lose exclusivity? Patent and exclusivity projection framework
H2-subsection: Exclusivity timeline inputs required for a defensible projection
A launch-expiry projection must connect:
- Patent estate for the specific Pregnyl formulation(s) and presentation(s) in each jurisdiction
- Regulatory exclusivity status (if any) linked to label approvals
- Whether the relevant product is protected as a formulation, method of use, or manufacturing process
Core projection mechanics
- Earliest possible generic entry date depends on:
- patent expiration dates
- pediatric exclusivity or other regulatory extensions (if applicable)
- any settlement-driven “at-risk” periods
- If there are no controlling patents (common for older biologic-like products depending on jurisdiction), the exclusivity timeline may be dominated by regulatory and data/market history rather than IP.
No patent numbers, assignees, filing dates, or jurisdiction coverage are provided in the request, and therefore a precise “loss of exclusivity” projection cannot be produced.
What patents protect Pregnyl and chorionic gonadotropin products? Which jurisdictions matter most?
H2-subsection: Patent estate mapping required
A protection map should list:
- patent numbers
- assignees
- priority and filing dates
- claim categories (formulation, method of use, manufacturing)
- status (granted, expired, litigated)
- jurisdictional coverage (US vs EP vs national filings)
Because no Pregnyl-specific patent list is provided, a patent-coverage count and expiration table cannot be assembled accurately.
What generic entry risks exist for Pregnyl based on FDA status and Paragraph IV pathways?
H2-subsection: Regulatory pathway dependence
For US FDA, risk depends on whether the product is:
- an NDA/AND A listed product with an Orange Book listing
- a biologic under a BLA with licensure pathway differences
- a non-Orange Book product where generic risk is handled via other regulatory frameworks
Without FDA label and regulatory listing data, Paragraph IV relevance for Pregnyl cannot be verified.
How does Pregnyl compare with competing hCG products in efficacy, dosing, and protocol fit?
H2-subsection: Comparative axes
A credible comparison must cover:
- unit potency specifications and dosing conversion (IU)
- route and administration instructions by label
- onset of action and use cases in ART triggers
- safety signals (thromboembolism risk varies with underlying protocols; OHSS risk depends on ovarian stimulation context)
No label-verified dose regimens or product strengths are provided, so a meaningful comparison cannot be created.
What to expect next: clinical development, supply, and pricing outcomes for Pregnyl
H2-subsection: Forward-looking projection categories
A useful projection needs:
- trial pipeline milestones (if any are active)
- manufacturing continuity and raw material availability for urinary hCG
- payer coverage shifts and tender dynamics by geography
- IP timeline triggers (expiration, injunction, settlements)
No forward-looking inputs are included, so no defensible projection can be produced.
Key Takeaways
- Pregnyl is an hCG product; a high-quality clinical-trials update and market projection require brand-tagged and label-tagged data by geography and indication.
- The request does not include trial registry extracts, FDA/EMA listing status, Orange Book/patent details, or current market/pricing benchmarks, so an accurate update and timeline cannot be produced.
FAQs
- What are the most common indications listed for Pregnyl by country?
- Are there active clinical trials where Pregnyl is the investigational product or comparator?
- How do urinary hCG products compare with recombinant hCG in clinical protocols?
- What regulatory listings and exclusivity statuses apply to Pregnyl in the US and EU?
- What is the likely competitive impact of lower-cost hCG alternatives on Pregnyl pricing?
References
No sources were cited because the necessary FDA/EMA, trial-registry, and patent/regulatory datasets were not supplied in the request.
